XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating activities:    
Net loss $ (10,993) $ (65,201)
Adjustments to reconcile net loss to cash used in operating activities:    
Acquired in-process research and development   23,049
Depreciation and amortization 93 86
Stock-based compensation 2,951 3,789
Net unrealized loss on foreign currency transactions 415 519
Amortization of term loan discount and issuance costs 180 152
Amortization of premium and accretion of discounts on investments (749) 103
Deferred revenue (6,826)  
Changes in operating assets and liabilities:    
Accounts receivable (931)  
Prepaid expenses and other current assets (1,055) 450
Accounts payable (323) 1,010
Accrued expenses 1,156 (476)
Right-of-use assets and lease liabilities, net (37) 61
Net cash provided by operating activities (16,119) (36,458)
Investing activities:    
Purchases of property and equipment (15) (277)
Purchases of short-term investments (37,181) (14,962)
Maturities of short-term investments 38,000 26,245
Cash acquired in Bioniz acquisition   700
Net cash used in investing activities 804 11,706
Financing activities:    
Repayment of notes payable (9,133)  
Common stock repurchased (260)  
Proceeds from issuance of common stock under employee stock purchase plan 86 141
Net cash (used in) provided by financing activities (9,307) 141
Effect of exchange rate changes on cash and cash equivalents (103) (26)
Net decrease in cash and cash equivalents (24,725) (24,637)
Cash and cash equivalents at beginning of period 59,107 50,366
Cash and cash equivalents at end of period $ 34,382 25,729
Supplemental cash flow information    
Fair value of Bioniz assets acquired   23,049
Issuance of common stock for Bioniz acquisition   (22,542)
Bioniz net liabilities assumed   507
Property and equipment in accounts payable   $ 3